18F-Labeled PET-Tracers for Cardiological Imaging

Fluorine and Health

Volumn , Issue , 2008, Pages 85-139

  Kopka, Klaus ^a,b   Wagner, Stefan ^a,b   Schäfers, Michael ^a,b   Faust, Andreas ^a,b   Schober, Otmar ^a,b   Haufe, Günter ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953383426     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-444-53086-8.00003-5     Document Type: Chapter

References (205)

1. Welch M.J., Redvanly C.S. Handbook of Radiopharmaceuticals 2003, John Wiley & Sons Ltd, Chichester, West Sussex, UK.
2. Neglia D., Sambuceti G., Iozzo P., L'Abbate A., Strauss H.W. Myocardial metabolic and receptor imaging in idiopathic dilated cardiomyopathy. Eur. J. Nucl. Med. 2002, 29:1403-1413.
3. 18F]-2-deoxy-2-fluoro-D-glucose. J. Nucl. Med. 1978, 19:1154-1161.
4. Smith T.A. Mammalian hexokinases and their abnormal expression in cancer. Br. J. Biomed. Sci. 2000, 57:170-178.
5. 18F]FDG uptake and PCNA, Glut-1, and Hexokinase II expressions in cancers and inflammatory lesions of the lung. Neoplasia 2005, 7:369-379.
6. Southworth R., Darling J.L., Medina R.A., Flynn A.A., Pedley R.B., Garlick P.B. Dissociation of glucose tracer uptake and glucose transporter distribution in the regionally ischemic isolated rat heart: Application of a new autoradiographic technique. Eur. J. Nucl. Med. Mol. Imaging 2002, 29:1334-1341.
7. Brock C.S., Meikle S.R., Price P. Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumors benefit oncology?. Eur. J. Nucl. Med. 1997, 24:691-705.
8. 18F]fluoro-2-deoxy-D-glucose. Appl. Radiat. Isot. 1996, 47:61-66.
9. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J. Nucl. Med. 1986, 27:235-238.
10. Schicha H., Schober O. Nuklearmedizin. Basiswissen und klinische Anwendung 2003, 20-54. Schattauer, Stuttgart, New York. 5th Edition.
11. 18F-fluoro-4-thia-palmitate as a PET probe for myocardial fatty acid oxidation: Effects of hypoxia and composition of exogenous fatty acids. J. Nucl. Med. 2006, 47:173-181.
12. Schwaiger M., Schelbert H.R., Keen R. Retention and clearence of C-11 palmitic acid in ischemic and reperfused canine myocardium. J. Am. Coll. Cardiol. 1985, 6:311-320.
13. Stanley W.C., Recchia F.A., Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 2005, 85:1093-1129.
14. Bergmann S.R., Herrero P., Sciacca R. Characterization of altered myocardial fatty acid metabolism in patients with inherited cardiomyopathy. J. Inherit. Metab. Dis. 2001, 24:657-674.
15. Stanley W.C., Lopaschuk G.D., McCormack J.G. Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc. Res. 1997, 34:25-33.
16. Folmes C.D., Clanachan A.S., Lopaschuk G.D. Fatty acid oxidation inhibitors in the management of chronic complications of atherosclerosis. Curr. Atheroscler. Rep. 2005, 7:63-70.
17. Di Napoli P., Taccardi A.A., Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischemic dilated cardiomyopathy. Heart 2005, 91:161-165.
18. Wambolt R.B., Lopaschuk G.D., Brownsey R.W. Dichloroacetate improves postischemic function of hypertrophied rat hearts. J. Am. Coll. Cardiol. 2000, 36:1378-1385.
19. 18F]-fluoro-6-thiaheptadecanoic acid (FTHA): Evaluation in mouse of a new probe of myocardial utilization of long chain fatty acids. J. Nucl. Med. 1991, 32:1888-1896.
20. 18F]-labelled 4-thia palmitate a pet tracer of myocardial fatty acid oxidation. Nucl. Med. Biol. 2000, 27:221-231.
21. 18F]-3-methyl-branched omega fluorofatty acids. J. Label. Compd. Radiopharm. 1989, 26:233-235.
22. 18F]-fatty acids for the study of regional metabolism in heart and liver; odd-even effects of metabolism in mice. J. Nucl. Med. 1979, 20:1170-1175.
23. 18F]-fluorofatty acid: A potential myocardial imaging tracer for positron emission tomography. Nucl. Med. Biol. 1996, 23:303-308.
24. 18F]-fluoro long chain fatty acid analogues show cytochrome P-450 mediated defluorination; implication for the design of PET-tracers of myocardial fatty acid utilization. Nucl. Med. Biol. 1992, 19:389-397.
25. 18F]-fluoro-6-thiaheptadecanoic acid in normal human hearts at rest, during exercise and after dipyridamole injection. J. Nucl. Med. 1994, 35:51-56.
26. Maki M.T., Haaparanta M., Nuutila P., Oikonen V., Luotolahti M., Eskola O., Knuuti J.M. Free fatty acid uptake in the myocardium and skeletal muscle using fluorine-18-fluoro-6-thia heptadecanoic acid. J. Nucl. Med. 1998, 39:1320-1327.
27. 18F]FDG in patients with congestive heart failure. J. Nucl. Med. 2001, 42:55-62.
28. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
29. Stary H.C., Chandler A.B., Dinsmore R.E., Fuster V., Glagov S., Insull W., Rosenfeld M.E., Schwartz C.J., Wagner W.D., Wissler R.W. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1995, 92:1355-1374.
30. Virmani R., Burke A.P., Kolodgie F.D., Farb A. Pathology of the thin-cap fibroatheroma: A type of vulnerable plaque. J. Interv. Cardiol. 2003, 16:267-272.
31. Libby P., Theroux P. Pathophysiology of coronary artery disease. Circulation 2005, 111:3481-3488.
32. Galis Z.S. Vulnerable plaque: The devil is in the details. Circulation 2004, 110:244-246.
33. Lederman R.J., Raylman R.R., Fisher S.J., Kison P.V., San H., Nabel E.G., Wahl R.L. Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG). Nucl. Med. Commun. 2001, 22:747-753.
34. 18 F-FDG accumulation in atherosclerotic plaques: Immunohistochemical and PET imaging study. J. Nucl. Med. 2004, 45:1245-1250.
35. 18 F-FDG uptake in the large arteries: A correlation study with the atherogenic risk factors. Semin. Nucl. Med. 2002, 32:70-76.
36. 18F]-fluorodeoxyglucose positron emission tomography. Circulation 2002, 105:2708-2711.
37. Tatsumi M., Cohade C., Nakamoto Y., Wahl R.L. Fluorodeoxyglucose uptake in the aortic wall at PET/CT: Possible finding for active atherosclerosis. Radiology 2003, 229:831-837.
38. 18F-fluorodeoxyglucose positron-emission tomography and high-resolution magnetic resonance imaging. Stroke 2005, 36:2642-2647.
39. Borkakoti N. Structural studies of matrix metalloproteinases. J. Mol. Med. 2000, 78:261-268.
40. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol. Rev. 2005, 85:1-31.
41. Kopka K., Breyholz H.J., Wagner S., Law M.P., Riemann B., Schröer S., Trub M., Guilbert B., Levkau B., Schober O., Schäfers M. Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo. Nucl. Med. Biol. 2004, 31:257-267.
42. Schäfers M., Riemann B., Kopka K., Breyholz H.J., Wagner S., Schäfers K.P., Law M.P., Schober O., Levkau B. Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo. Circulation 2004, 109:2554-2559.
43. 11C]Methyl-CGS27023A: A new PET breast cancer imaging agent. J. Label. Compd. Radiopharm. 2001, 44:S104-S106.
44. 11C]methyl-CGS 27023A and its analogs, new potential PET breast cancer imaging agents. J. Label. Compd. Radiopharm. 2002, 45:449-470.
45. Furumoto S., Iwata R., Ido T. Design and synthesis of fluorine-18 labeled matrix metalloproteinase inhibitors for cancer imaging. J. Label. Compd. Radiopharm. 2002, 45:975-986.
46. 18F-labeled matrix metalloproteinase-2 inhibitor. Nucl. Med. Biol. 2003, 30:119-125.
47. Hickey K.A., Rubanyi G., Paul R.J., Highsmith R.F. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am. J. Physiol. 1985, 248:C550-C556.
48. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
49. Saito Y., Nakao K., Mukoyama M., Imura H. Increased plasma endothelin level in patients with essential hypertension. N. Engl. J. Med. 1990, 322:205.
50. Teerlink J., Loeffler B.M., Hess P., Maire J.P., Clozel M., Clozel J.P. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation 1994, 90:2510-2518.
51. Giaid A., Yanagisawa M., Langleben D., Michel R., Levy R., Shennib H., Kimura S., Masaki T., Duguid W., Path F.R.C., Stewart D.J. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 1993, 328:1732-1739.
52. Masaki T., Yanagisawa M., Goto K. Physiology and pharmacology of endothelins. Med. Res. Rev. 1992, 12:391-421.
53. Nelson J., Bagnato A., Battistini B., Nisen P. The endothelin axis: Emerging role in cancer. Nat. Rev. Cancer 2003, 3:110-116.
54. Dhaun N., Goddard J., Webb D. The endothelin system and its antagonism in chronic kidney disease. J. Am. Soc. Nephrol. 2006, 17:943-955.
55. Pittman Q.J. Endothelin-an emerging role in proinflammatory pathways in brain. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 290:R162-R163.
56. B receptor function in pancreatitis-associated microcirculatory failure, inflammation, and parenchymal injury. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 285:G145-G153.
57. Sakurai T., Yanagisawa M., Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol. Sci. 1992, 13:103-108.
58. Battistini B., Chailler P., D'Orleans-Juste P., Briere N., Sirios P. Growth regulatory properties of endothelins. Peptides 1993, 14:385-399.
59. Levin E.R. Endothelins. N. Engl. J. Med. 1995, 333:356-363.
60. Goldie R.G. Endothelins in health and disease: An overview. Clin. Exp. Pharmacol. Physiol. 1999, 26:145-148.
61. Davenport A.P., Battistini B. Classification of endothelin receptors and antagonists in clinical development. Clin. Sci. 2002, 103:1S-3S.
62. Webb M.L., Meek T.D. Inhibitors of endothelin. Med. Res. Rev. 1997, 17:17-67.
63. A receptor selectivity. Bioorg. Med. Chem. 1999, 7:991-1002.
64. B affinity. Bioorg. Med. Chem. Lett. 1998, 8:2241-2246.
65. B receptor antagonist. J. Med. Chem. 1999, 42:3026-3032.
66. 18 F-Endothelin-1, a positron emission tomography (PET) radioligand for the endothelin receptor system: Radiosynthesis and in vivo imaging using microPET. Cli. Sci. 2002, 103:4S-8S.
67. B receptors in vivo. Br. J. Pharmacol. 2005, 144:115-122.
68. Johnström P., Aigbirhio F.I., Clark J.C., Downey S.P.M.J., Pickard J.D., Davenport A.P. Syntheses of the first endothelin-A- and -B-selective radioligands for positron emission tomography. J. Cardiovasc. Pharmacol. 2000, 36:S58-S60.
69. 18F]-SB209670 and positron emission tomography (microPET). J. Cardiovasc. Pharmacol. 2004, 44:S34-S38.
70. Elliott J.D., Lago M.A., Cousins R.D., Gao A., Leber J.D., Erhard K.F., Nambi P., Elshourbagy N.A., Kumar C., Lee J.A., Bean J.B., DeBrosse C.W., Eggleston D.S., Brooks D.P., Feuerstein G., Ruffolo R.R., Weinstock J., Gleason J.G., Peishoff C.E., Ohlstein E.H. 1,3-Diarylindan-2-carboxylic acids potent and selective non-peptide endothelin receptor antagonists. J. Med. Chem. 1994, 37:1553-1557.
71. 18F-labeled potential myocardial blood flow tracers. Nucl. Med. Biol. 2001, 28:683-693.
72. 201Tl. J. Nucl. Med. 2004, 45:1950-1959.
73. Ueno H., Miyoshi H., Ebisui K., Iwamura H. Comparison of the inhibitory action of natural rotenone and its stereoisomers with various NADH-ubiquinone reductases. Eur. J. Biochem. 1994, 225:411-417.
74. Ueno H., Miyoshi H., Inoue M., Niidome Y., Iwamura H. Structural factors of rotenone required for inhibition of various NADH-ubiquinone oxidoreductases. Biochim. Biophys. Acta 1996, 1276:195-202.
75. Greenamyre J.T., Higgins D.S., Ellers R.V. Quantitative autoradiography of dihydrorotenone binding to complex I of the electron transport chain. J. Neurochem. 1992, 59:746-749.
76. Ramsay R.R., Krueger M.J., Youngster S.K., Gluck M.R., Casida J.E., Singer T.P. Interaction of 1-methyl-4-phenylpyridinium ion (MPP+) and its analogs with the rotenone/piericidin binding site of NADH dehydrogenase. J. Neurochem. 1991, 56:1184-1190.
77. Riemann B., Schäfers M., Law M.P., Wichter T., Schober O. Radioligands for imaging myocardial α- and β-adrenoceptors. Nuklearmedizin 2003, 42:4-9.
78. Carrio I. Cardiac neurotransmission imaging. J. Nucl. Med. 2001, 42:1062-1076.
79. Langer O., Halldin C. PET and SPET tracers for mapping the cardiac nervous system. Eur. J. Nucl. Med. Mol. Imaging 2002, 29:416-434.
80. Elsinga P.H., van Waarde A., Vaalburg W. Receptor imaging in the thorax with PET. Eur. J. Pharmacol. 2004, 499:1-13.
81. Pike V.W., Law M.P., Osman S., Davenport R.J., Rimoldi O., Giardina D., Camici P.G. Selection design and evaluation of new radioligands for PET studies of cardiac adrenoceptors. Pharm. Acta Helv. 2000, 74:191-200.
82. Kopka K., Law M.P., Breyholz H.J., Faust A., Höltke C., Riemann B., Schober O., Schäfers M., Wagner S. Non-invasive molecular imaging of β-adrenoceptors in vivo: Perspectives for PET-radioligands. Curr. Med. Chem. 2005, 12:2057-2074.
83. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 2000, 21:90-113.
84. Lands A.M., Arnold A., McAuliff J.P., Luduena F.P., Brown T.G. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967, 214:597-598.
85. Arch J.R., Ainsworth A.T., Cawthorne M.A., Piercy V., Sennitt M.V., Thody V.E., Wilson C., Wilson S. Atypical β-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 1984, 309:163-165.
86. Bond R.A., Clarke D.E. Agonist and antagonist characterization of a putative adrenoceptor with distinct pharmacological properties from the α- and β-subtypes. Br. J. Pharmacol. 1988, 95:723-734.
87. Sarsero D., Molenaar P., Kaumann A.J., Freestone N.S. Putative β4-adrenoceptors in rat ventricle mediate increases in contractile force and cell Ca2+: Comparison with atrial receptors and relationship to (-)-[3H]-CGP 12177 binding. Br. J. Pharmacol. 1999, 128:1445-1460.
88. Brodde O.E., Leineweber K. Autonomic receptor systems in the failing and aging human heart: Similarities and differences. Eur. J. Pharmacol. 2004, 500:167-176.
89. Brodde O.E. β1- and β2-adrenoceptors in the human heart: Properties, function, and alterations in chronic heart failure. Pharmacol. Rev. 1991, 43:203-242.
90. Castellano M., Böhm M. The cardiac β-adrenoceptor-mediated signaling pathway and its alterations in hypertensive heart disease. Hypertension 1997, 29:715-722.
91. Khamssi M., Brodde O.E. The role of cardiac β1- and β2-adrenoceptor stimulation in heart failure. J Cardiovasc Pharmacol 1990, 16(Suppl 5):S133-S137.
92. Brodde O.E., Zerkowski H.R., Doetsch N., Motomura S., Khamssi M., Michel M.C. Myocardial β-adrenoceptor changes in heart failure: Concomitant reduction in β1- and β2-adrenoceptor function related to the degree of heart failure in patients with mitral valve disease. J. Am. Coll. Cardiol. 1989, 14:323-331.
93. Anthonio R.L., Brodde O.E., van Veldhuisen D.J., Scholtens E., Crijns H.J., van Gilst W.H. β-adrenoceptor density in chronic infarcted myocardium: A subtype specific decrease of β1-adrenoceptor density. Int. J. Cardiol. 2000, 72:137-141.
94. Yamada S., Ohkura T., Uchida S., Inabe K., Iwatani Y., Kimura R., Hoshino T., Kaburagi T. A sustained increase in β-adrenoceptors during long-term therapy with metoprolol and bisoprolol in patients with heart failure from idiopathic dilated cardiomyopathy. Life Sci. 1996, 58:1737-1744.
95. Elsinga P.H., Doze P., Maas A., van Waarde A., Wegman T., Vaalburg W. Synthesis and evaluation of radiolabelled antagonists for β-adrenoceptor imaging in the brain with PET. J. Label. Compd. Radiopharm. 2001, 44:S262-S264.
96. 18F]-fluoropropranolol, a lipophilic ligand for the β-adrenergic receptor. Nucl. Med. Biol. 1999, 26:891-896.
97. 18F]fluoro-CGP 12388) for visualization of β-adrenoceptors with positron emission tomography. J. Med. Chem. 1997, 40:3829-3835.
98. Doze P., Elsinga P.H., Maas B., van Waarde A., Wegman T., Vaalburg W. Synthesis and evaluation of radiolabeled antagonists for imaging of β-adrenoceptors in the brain with PET. Neurochem. Int. 2002, 40:145-155.
99. 18F]fluorocarazolol ligands for the visualization of pulmonary β-adrenergic receptors with PET. Nucl. Med. Biol. 1996, 23:159-167.
100. 18F]fluorocarazolol. J. Nucl. Med. 1997, 38:934-939.
101. Visser T.J., van Waarde A., van der Mark T.W., Kraan J., Elsinga P.H., Pruim J., Ensing K., Jansen T., Willemsen A.T., Franssen E.J., Visser G.M., Paans A.M., Vaalburg W. Characterization of pulmonary and myocardial β-adrenoceptors with (S)-1′-[fluorine-18]fluorocarazolol. J. Nucl. Med. 1997, 38:169-174.
102. Doze P., Elsinga P.H., de Vries E.F., van Waarde A., Vaalburg W. Mutagenic activity of a fluorinated analog of the β-adrenoceptor ligand carazolol in the Ames test. Nucl. Med. Biol. 2000, 27:315-319.
103. 18F]fluorometoprolol as a potential tracer for the visualization of β-adrenoceptors with PET. Nucl. Med. Biol. 1993, 20:637-642.
104. Posakony J.J., Tewson T.J. [18F]-Labeled β1-selective ligands for imaging the adrenergic receptors of the heart. J. Label. Compd. Radiopharm. 2001, 44:S416-S417.
105. 18F]-fluoroethylcarazolol for in vivo β-adrenoceptor imaging in the brain. Neurochem. Int. 2002, 41:17-27.
106. 18F]FEFE) for the in vivo visualisation and quantification of the β2-adrenergic receptor status in lung. Bioorg. Med. Chem. Lett. 2003, 13:2687-2692.
107. 18(F-labelled high affinity β1-adrenoceptor PET radioligand based on ICI 89,406. J. Label. Compd. Radiopharm. 2006, 49:177-195.
108. Starke K. α-Adrenoceptor subclassification. Rev. Physiol. Biochem. Pharmacol. 1981, 88:199-236.
109. Civantos Calzada B., Aleixandre de Artinano A. α-Adrenoceptor subtypes. Pharmacol. Res. 2001, 44:195-208.
110. Bristow M.R. Changes in myocardial and vascular receptors in heart failure. J. Am. Coll. Cardiol. 1993, 22(4 Suppl A):61A-71A.
111. 1-Adrenergic receptors in the nonfailing and failing human heart. J. Pharmacol. Exp. Ther. 1988, 247:1039-1045.
112. Heusch G. α-Adrenergic mechanisms in myocardial ischemia. Circulation 1990, 81:1-13.
113. Hieble J.P. Adrenoceptor subclassification: An approach to improved cardiovascular therapeutics. Pharm. Acta. Helv. 2000, 74:163-171.
114. 2-adrenoceptor antagonists as potential brain imaging agents. Neuropharmacology 2004, 46:847-855.
115. 2-adrenoceptors. Int. J. Rad. Appl. Instrum. B 1992, 19:841-849.
116. Dhein S., van Koppen C.J., Brodde O.E. Muscarinic receptors in the mammalian heart. Pharmacol. Res. 2001, 44:161-182.
117. 3 receptor subtype gene expression in the human heart. Cell Mol. Life Sci. 2000, 57:175-180.
118. Le Guludec D., Cohen-Solal A., Delforge J., Delahaye N., Syrota A., Merlet P. Increased myocardial muscarinic receptor density in idiopathic dilated cardiomyopathy: an in vivo PET study. Circulation 1997, 96:3416-3422.
119. 18F]-fluoromethyl QNB. Bioorg. Med. Chem. 1997, 5:1555-1567.
120. Kiesewetter D.O., Silverton J.V., Eckelman W.C. Syntheses and biological properties of chiral fluoroalkyl quinuclidinyl benzilates. J. Med. Chem. 1995, 38:1711-1719.
121. 2 selectivity. J. Med. Chem. 1995, 38:5-8.
122. 18F]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice. Neuropharmacology 2003, 44:653-661.
123. Benson B.E., Carson R.E., Kiesewetter D.O., Herscovitch P., Eckelman W.C., Post R.M., Ketter T.A. A potential cholinergic mechanism of procaine's limbic activation. Neuropsychopharmacology 2004, 29:1239-1250.
124. 18F]FP-TZTP: Control and competition studies. J. Cereb. Blood Flow Metab. 1998, 18:1130-1142.
125. 2 muscarinic receptor?. Eur. J. Nucl. Med. Mol. Imaging 2006, 33:292-300.
126. 18F]fluoroethyl)-4-piperidyl benzilate binding to muscarinic acetylcholine receptors. J. Cereb. Blood Flow Metab. 2001, 21:144-148.
127. 18F-labeling, and biological evaluation of piperidyl and pyrrolidyl benzilates as in vivo ligands for muscarinic acetylcholine receptors. J. Med. Chem. 2000, 43:4552-4562.
128. 18F]fluorodexetimide. Syntheses and biodistribution. Int. J. Rad. Appl. Instrum. B 1991, 18:247-252.
129. 18F]-fluorodexetimide. Life Sci. 1991, 48:1385-1394.
130. Luo H., Beets A.L., McAllister M.J., Greenbaum M., McPherson D.W., Knapp F.F. Resolution, in vitro and in vivo evaluation of fluorine-18-labeled isomers of 1-azabicyclo[2.2.2]oct-3-yl α -(1-fluoropent-5-yl)- α -hydroxy- α -phenylacetate (FQNPe) as new PET candidates for the imaging of muscarinic-cholinergic receptor. J. Label. Compd. Radiopharm. 1998, 41:681-704.
131. Luo H., Hasan A., Sood V., McRee R.C., Zeeberg B., Reba R.C., McPherson D.W., Knapp F.F. Evaluation of 1-azabicyclo[2.2.2]oct-3-yl α-fluoroalkylα-hydroxyα-phenylacetates as potential ligands for the study of muscarinic receptor density by positron emission tomography. Nucl. Med. Biol. 1996, 23:267-276.
132. Amara S.G. Neurotransmitter transporters: Recent progress. Annu. Rev. Neurosci. 1993, 16:73-79.
133. Brownstein M.J., Hoffman B.J. Neurotransmitter transporters. Recent Prog. Hormone Res. 1994, 49:27-42.
134. Borowsky B., Hoffmann B.J. Neurotransmitter transporters: Molecular biology function and regulation. Int. Rev. Neurobiol. 1995, 38:139-198.
135. Parsons S.M. Transport mechanism in acetylcholine and monoamine storage. FASEB J. 2000, 14:2423-2434.
136. Weihe E., Eiden L.E. Chemical neuroanatomy of the vesicular amine transporters. FASEB J. 2000, 14:2435-2449.
137. Kopin I.J. False adrenergic transmitters. Annu. Rev. Pharmacol. 1968, 8:377-394.
138. Barker E.L., Blakely R.D. Psychopharmacology: The fourth generation of progress 1995, 321-333. Raven Press, New York. F.E. Bloom, D.J. Kupfer (Eds.).
139. 18F]fluorodopamine for positron emission tomography studies of sympathetic nervous tissue. J. Med. Chem. 1991, 34:861-863.
140. 18F]fluorodopamine: Initial findings in humans. J. Am. Coll. Cardiol. 1993, 22:1961-1971.
141. 18F]fluorodopamine with a synthetic unit made up of primarily sterile disposable components and operated by master slave manipulator. Appl. Radiat. Isot. 1993, 44:869-873.
142. 18F-labeled 6-fluorodopamine for imaging cardiac sympathetic innervation in humans using positron emission tomography. Nucl. Med. Biol. 1996, 23:41-45.
143. Goldstein D.S., Chang P.C., Eisenhofer G., Miletich R., Finn R., Bacher J., Kirk K.L., Bacharach S., Kopin I.J. Positron emission tomographic imaging of cardiac sympathetic innervation and function. Circulation 1990, 81:1606-1621.
144. 18F]6-flurodopamine as a measure of cardiac sympathetic activity in humans. Heart 1996, 75:29-34.
145. 18F]fluorodopamine positron emission tomographic scanning in the assessment of cardiac sympathoneural function-studies in normal humans. Clin. Auton. Res. 1997, 7:17-29.
146. Goldstein D.S., Holmes C., Cannon R.O., Eisenhofer G., Kopin I.J. Sympathetic cardioneuropathy in dysautonomias. N. Engl. J. Med. 1997, 336:696-702.
147. Fallen E.L., Coates G., Nahmias C., Chirakal R., Beanlands R., Wahl L., Woodcock G., Thomson M., Kamath M. Recovery rates of regional sympathetic reinnervation and myocardial blood flow after acute myocardial infarction. Am. Heart J. 1999, 137:863-869.
148. Goldstein D.S., Holmes C., Li S.T., Bruce S., Metman L.V., Cannon R.O. Cardiac sympathetic denervation in Parkinson disease. Ann. Intern. Med. 2000, 133:338-347.
149. Li S.T., Tack C.J., Fananapazir L., Goldstein D.S. Myocardial perfusion and sympathetic innervation in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2000, 35:1867-1873.
150. 18F-fluorodopamine PET scanning. J. Nucl. Med. 2003, 44:1599-1603.
151. Eldadah B.A., Pacak K., Eisenhofer G., Holmes C., Kopin I.J., Goldstein D.S. Cardiac uptake-1 inhibition by high circulating norepinephrine levels in patients with pheochromocytoma. Hypertension 2004, 43:1227-1232.
152. Moak J.P., Eldadah B., Holmes C., Pechnik S., Goldstein D.S. Partial cardiac sympathetic denervation after bilateral thoracic sympathectomy in humans. Heart Rhythm. 2005, 2:602-609.
153. Chiueh C.C., Zukowska-Grojec Z., Kirk K.L., Kopin I.J. 6-Fluorocatecholamines as false adrenergic neurotransmitters. J. Pharmacol. Exp. Ther. 1983, 225:529-533.
154. Kirk K.L., Jayachandran B., Herbert B., Lu S.F., Padgett W.L., Daly J.W., Haufe G., Laue K.W. Chemical and biological approaches to non-racemic fluorinated catecholamines and amino acids. ACS Symposium Series 2000, 746:194-209.
155. Lu S.F., Haufe G., Laue K.W., Padgett W.L., Oshunleti O., Daly J.W., Kirk K.L. Syntheses of (R)- and (S)-2- and 6-fluoronorepinephrine and (R)- and (S)-2- and 6-fluoro-epinephrine: Effect of stereochemistry on fluorine-induced adrenergic selectivities. J. Med. Chem. 2000, 43:1611-1619.
156. 18F]fluoronorepinephrine via the nucleophilic aromatic substitution reaction. J. Med. Chem. 1991, 34:767-771.
157. 18F]-fluorodopamine by dopamine β-hydroxylase. J. Label. Compd. Radiopharm. 1998, 41:503-521.
158. 18F]fluorodopamine in baboons: Heart uptake, metabolism and the effect of desipramine. J. Nucl. Med. 1993, 34:619-629.
159. Fowler J.S., Ding Y.S., Volkow N.D., Martin T., MacGregor R.R., Dewey S., King P., Pappas N., Alexoff D., Shea C., Gatley S.J., Schlyer D.J., Wolf A.P. PET studies of cocaine inhibition of myocardial norepinephrine uptake. Synapse 1994, 16:312-317.
160. 18F]fluorodopamine in living baboon heart: Selective imaging and control of radiotracer metabolism using the deuterium isotope effect. J. Neurochem. 1995, 65:682-690.
161. Fuller R.W., Snoddy H.D., Perry K.W., Bernstein J.R., Murphy P.J. Formation of α-methylnorepinephrine as a metabolite of metaraminol in guinea pigs. Biochem. Pharmacol. 1981, 30:2831-2836.
162. Andén N.E. On the mechanism of noradrenaline depletion by α-methyl metatyrosine and metaraminol. Acta Pharmacol. Toxicol. 1964, 21:260-271.
163. Shore P.A., Busfield D., Alpers H.S. Binding and release of metaraminol: Mechanism of norepinephrine depletion by α-methyl-m-tyrosine and related reagents. J. Pharmacol. Exp. Ther. 1964, 146:194-199.
164. Crout J.R., Alpers H.S., Tatum E.L., Shore P.A. Release of metaraminol (aramine) from the heart by sympathetic nerve stimulation. Science 1964, 145:828-829.
165. 3H-metaraminol by different mechanisms. Acta Physiol. Scand. 1966, 67:471-480.
166. Carlsson A., Waldeck B. Different mechanisms of drug-induced release of noradrenaline and its congeners α-methyl-noradrenaline and metaraminol. Eur. J. Pharmacol. 1968, 4:165-168.
167. Johnson R.G., Carty S.E., Hayflick S., Scarpa A. Mechanisms of accumulation of tyramine, metaraminol, and isoproterenol in isolated chromaffin granules and ghosts. Biochem. Phamacol. 1982, 31:815-823.
168. 18F]fluorometaraminol: A radiotracer for in vivo mapping of adrenergic nerves of the heart. J. Med. Chem. 1988, 31:362-366.
169. 18F]fluorometaraminol. J. Med. Chem. 1990, 33:956-964.
170. 18F]fluorometaraminol, a tracer for the assessment of cardiac sympathetic nerve integrity with PET. Nucl. Med. Biol. 2004, 31:103-110.
171. 18F-labelled sympathomimetics based on norepinephrine. J. Label. Compd. Radiopharm. 1997, 40:53-56.
172. 18F]fluorometaraminol: A PET radiotracer for mapping sympathetic nerves of the heart. Nucl. Med. Biol. 2000, 27:233-238.
173. 18F]fluorometaraminol-PET tracers for the adrenergic nervous system of the heart. Bioorg. Med. Chem. 2001, 9:677-694.
174. 18F]6-fluorometaraminol. Int. J. Rad. Appl. Instrum. B 1989, 16:735-739.
175. Schwaiger M., Guibourg H., Rosenspire K., McClanahan T., Gallagher K., Hutchins G., Wieland D.M. Effect of regional myocardial ischemia on sympathetic nervous system as assessed by fluorine-18-metaraminol. J. Nucl. Med. 1990, 31:1352-1357.
176. 123I-MIBG in normotensive and spontaneously hypertensive rats. J. Nucl. Med. 2002, 43:366-373.
177. Haaparanta M., Gronroos T., Eskola O., Bergman J., Solin O. Planar chromatographic analysis and quantification of short-lived radioactive metabolites from microdialysis fractions. J. Chromatogr. A 2006, 1108:136-139.
178. 18F]fluorobenzylguanidine. Nucl. Med. Biol. 1994, 21:87-103.
179. Berry C.R., Garg P.K., Zalutsky M.R., Coleman R.E., DeGrado T.R. Uptake and retention kinetics of para-fluorine-18-fluorobenzylguanidine in isolated rat heart. J. Nucl. Med. 1996, 37:2011-2016.
180. 18F]fluorobenzylguanidine. Vet. Radiol. Ultrasound 2002, 43:183-186.
181. 18F]fluorobenzylguanidine kinetics in a canine coronary artery occlusion model. J. Nucl. Cardiol. 1996, 3:119-129.
182. 18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography. J. Med. Chem. 1994, 37:3655-3662.
183. 18F]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J. Nucl. Med. 1995, 36:644-650.
184. Tuunanen H., Kuusisto J., Toikka J., Jaaskelainen P., Marjamaki P., Peuhkurinen K., Viljanen T., Sipola P., Stolen K.Q., Hannukainen J., Nuutila P., Laakso M., Knuuti J. Myocardial perfusion, oxidative metabolism, and free fatty acid uptake in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene: A positron emission tomography study. J. Nucl. Cardiol. 2007, 14:354-365.
185. 18F-FTHA: Plasma and tissue partitioning between lipid pools during fasting and hyperinsulinemia. J. Nucl. Med. 2007, 48:455-462.
186. 18F]Fluoro-6-thia-heptadecanoic acid in rats. Mol. Imaging Biol. 2006, 8:237-244.
187. 18F-fluoro-4-thia-palmitate as a PET probe for myocardial fatty acid oxidation: Effects of hypoxia and composition of exogenous fatty acids. J. Nucl. Med. 2006, 47:173-181.
188. 18F-fluoro-3,4-methyleneheptadecanoic acid as a PET tracer for myocardial fatty acid imaging. J. Nucl. Med. 2005, 46:297-304.
189. Tawakol A, Migrino R.Q., Hoffmann U., Abbara S, Houser S, Gewirtz H, Muller J.E., Brady T.J, Fischman A.J Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J. Nucl. Cardiol. 2005, 12:294-301.
190. 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques. J. Nucl. Med. 2006, 47:1845-1850.
191. 18 Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: Implications for atherosclerosis therapy trials. J. Am. Coll. Cardiol. 2007, 50:892-896.
192. 18F-FDG PET/CT in patients with carotid atherosclerosis and correlation with matrix metalloproteinase-1. J. Nucl. Med. 2007, 48:227-233.
193. 18 F-FDG accumulation in atherosclerosis: Use of CT and MR co-registration of thoracic and carotid arteries, Eur. J. Nucl. Med. Mol. Imaging 2006, 33:589-594.
194. Tahara N., Kai H., Ishibashi M., Nakaura H., Kaida H., Baba K., Hayabuchi N., Imaizumi T. Simvastatin attenuates plaque inflammation: Evaluation by fluorodeoxyglucose positron emission tomography. J. Am. Coll. Cardiol 2006, 48:1825-1831.
195. 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J. Am. Coll. Cardiol. 2006, 48:1818-1824.
196. Bural G.G., Torigian D.A., Chamroonrat W., Alkhawaldeh K., Houseni M., El-Haddad G., Alavi A. Quantitative assessment of the atherosclerotic burden of the aorta by combined FDG-PET and CT image analysis: A new concept. Nucl. Med. Biol. 2006, 33:1037-1043.
197. 18F-radiolabeled analogue of CGS 27023A as a potential agent for assessment of matrix-metalloproteinase activity in vivo. Q. J. Nucl. Med. Mol. Imaging 2007, 51:24-32.
198. Wagner S., Breyholz H.J., Law M.P., Faust A., Höltke C., Schröer S., Haufe G., Levkau B., Schober O., Schäfers M., Kopka K. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET. J. Med. Chem. 2007, 50:5752-5764.
199. 18F]-BQ3020: In vitro characterization and positron emission tomography (microPET). Exp. Biol. Med. (Maywood) 2006, 231:736-740.
200. 18F-fluorobenzyl triphenyl phosphonium in dog myocardium. J. Nucl. Med. 2006, 47:1359-1366.
201. 99mTc-tetrofosmin. J. Nucl. Med. 2007, 48:1021-1030.
202. 18F-fluorobenzyl triphenylphosphonium cation. Eur. J. Nucl. Med. Mol. Imaging 2007, Sep 5, [Epub ahead of print].
203. Goldstein D.S., Eldadah B.A., Holmes C., Pechnik S., Moak J., Saleem A., Sharabi Y. Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: Independence from levodopa treatment. Hypertension 2005, 46:1333-1339.
204. Goldstein D.S., Sharabi Y., Karp B.I., Bentho O., Saleem A., Pacak K., Eisenhofer G. Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clin. Auton. Res. 2007, 17:118-121.
205. Goldstein D.S. Cardiac denervation in patients with Parkinson disease. Cleve. Clin. J. Med. 2007, 74(Suppl. 1):S91-S94.